SAN CARLOS, Calif. & LISBON, Portugal--March 7, 2024--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a...
FlowCardia, acquired by C. R. Bard in 2010, developed and marketed products for the treatment of chronic total occlusions (CTOs) of coronary and peripheral arteries. Utilizing a technology known as high-frequency mechanical recanalization, the company developed the CROSSER™ System to safely and quickly break up CTOs allowing subsequent stent placement or balloon angioplasty and avoiding the trauma of cardiac surgery.
FlowCardia
Sunnyvale, CA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.